KRAS G12C inhibitors for non-small cell lung cancer — the mutation-specific small-molecule targeting of the historically "undruggable" KRAS oncogene representing the fastest-growing drug class in the global RAS-acting agents market — creates the most commercially transformative market segment, with the RAS-Acting Agents Market reflecting KRAS G12C inhibition as the premium growth...